We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.
- Authors
Jun Ishihara; Kazuto Fukunaga; Ako Ishihara; Larsson, Hans M.; Potin, Lambert; Hosseinchi, Peyman; Galliverti, Gabriele; Swartz, Melody A.; Hubbell, Jeffrey A.
- Abstract
The article focuses on the study on the antitumor efficacy and adverse event reduction of matrix-binding checkpoint immunotheraphies. Topics discussed include the conjugated checkpoint blockade antibodies (Abs) into extracellular matrix (ECM)-super-affinity peptide, the observation of tissue retention and Ab concentrations in the blood plasma, and the significant of conjugation on the reduction of side effects such as autoimmune diabetes.
- Subjects
TUMOR immunology; IMMUNOTHERAPY; TUMOR treatment; ADVERSE health care events; IMMUNOGLOBULINS; HEALTH outcome assessment; PREVENTION
- Publication
Science Translational Medicine, 2017, Vol 9, Issue 415, p1
- ISSN
1946-6234
- Publication type
Article
- DOI
10.1126/scitranslmed.aan0401